Angiodynamics
Angiodynamics' revenue rose 9.5% to $320 million in fiscal 2026. Its operating margin was −12.5%, up from −13.7% a year earlier. Free cash flow was $1 million. The diluted share count rose 1.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Angiodynamics does
AngioDynamics makes and sells medical devices used by doctors to treat cardiovascular disease and cancer. It was founded in 1988 in Queensbury, New York, and is headquartered in Latham, New York, with most manufacturing in Queensbury.
It reports two segments, Med Tech and Med Device. Products include the Auryon atherectomy system, a laser device that removes plaque from clogged leg arteries in peripheral artery disease, and the NanoKnife system, which it lists among its ablation products, used to destroy tumors. It also sells vascular access, drainage, embolization and venous products. The 10-K says all of the products it describes are cleared for sale in the United States by the FDA, and that clearances abroad vary by product and country.
The company has reshaped its lineup over the years through acquisitions and sales. In 2023 it sold its dialysis and BioSentry businesses to Merit Medical, and in 2024 it sold its PICC and Midline businesses to Spectrum Vascular. It says it relies heavily on third-party distributors for much of its international revenue.
Its biggest risks, as it describes them
- Intense competition and consolidation in the medical device industry could hurt its sales and prices.
- Failing to develop, acquire or market new products and technologies.
- Its business depends on completing clinical trials, including its Ambition BTK study, which may be halted or fail.
- Reliance on single or limited-source suppliers that could interrupt its supply.
- Heavy reliance on third-party distributors for international sales.
Income statement
From fiscal 2017 to 2019, earnings per share grew 242.3% a year and net income 250.1% a year, as new shares raised the share count by 2% and diluted each share's earnings. Angiodynamics then lost money in fiscal 2020, 2021, 2022, 2023, 2024, 2025 and 2026.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 29 | 45 | 76 | 56 | 54 |
| Debt incl. finance leases | 25 | 50 | 0 | 6 | 6 |
| Net debt (negative means net cash) | −4 | 5 | −76 | −50 | −48 |
| Net debt to EBITDA | −4.4x | — | — | — | — |
| Debt to equity | 0.1x | 0.1x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −41.4x | −18.9x | −119.2x | −216.0x | −93.7x |
| Current ratio | 1.9x | 1.9x | 2.1x | 2.2x | 2.2x |
| Quick ratio | 1.2x | 1.3x | 1.5x | 1.4x | 1.5x |
Cash flow
Projections
Project Angiodynamics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Angiodynamics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 5 of 9 | 4 of 9 |
| Rule of 40 | −20.4% | −8.8% | 9.6% |
| Altman Z'' | −4.09 | −1.82 | −2.65 |
| Accruals ratio | −36.7% | −8.0% | −14.6% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 3 of 9 | 5 of 9 | 4 of 9 |
Compare
Put Angiodynamics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Angiodynamics | FY26 | 9.5% | −12.5% | 0.2% | −24.6% | — | 4 | |
| Tactile Systems Technology | FY25 | 12.5% | 8.9% | 12.3% | 12.6% | −2.3x | 8 | Compare |
| PROCEPT BioRobotics | FY25 | 37.2% | −33.7% | −18.9% | −65.4% | — | 5 | Compare |
| LeMaitre Vascular | FY25 | 13.5% | 27.2% | 29.8% | 25.5% | −2.4x | 5 | Compare |
| STAAR Surgical | FY25 | −23.7% | −38.3% | −16.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 270 | 262 | 271 | 264 | 291 | 316 | 339 | 304 | 292 | 320 |
| Revenue growth | −23.8% | −3.0% | 3.4% | −2.4% | 10.2% | 8.7% | 7.1% | −10.3% | −3.8% | 9.5% |
| Gross profit | 144 | 144 | 156 | 150 | 157 | 166 | 174 | 155 | 158 | 175 |
| Research and development | 24 | 24 | 28 | 30 | 36 | 31 | 30 | 32 | 26 | 29 |
| Operating income | −11 | −14 | −9 | −167 | −35 | −28 | −51 | −192 | −40 | −40 |
| Net income | 5 | 16 | 61 | −167 | −32 | −26 | −52 | −184 | −34 | −37 |
| Diluted EPS (US$) | 0.14 | 0.44 | 1.64 | −4.39 | −0.82 | −0.68 | −1.33 | −4.59 | −0.83 | −0.88 |
| Diluted shares (millions) | 37 | 37 | 38 | 38 | 38 | 39 | 40 | 40 | 41 | 42 |
| Cash flow | ||||||||||
| Cash from operations | 56 | 41 | 37 | −15 | 24 | −7 | 0 | −28 | −10 | 3 |
| Capital expenditure | 3 | 2 | 3 | 7 | 5 | 4 | 4 | 2 | 4 | 3 |
| Free cash flow | 53 | 39 | 34 | −22 | 19 | −11 | −4 | −31 | −15 | 1 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 8 | 9 | 8 | 9 | 11 | 11 | 10 | 10 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 49 | 75 | 228 | 54 | 48 | 29 | 45 | 76 | 56 | 54 |
| Debt incl. finance leases | 96 | 92 | 132 | — | — | 25 | 50 | 0 | 6 | 6 |
| Total assets | 708 | 706 | 836 | 594 | 561 | 553 | 533 | 318 | 280 | 267 |
| Total liabilities | 193 | 163 | 222 | 139 | 122 | 128 | 154 | 112 | 97 | 96 |
| Shareholders' equity | 515 | 543 | 615 | 455 | 440 | 424 | 378 | 206 | 183 | 171 |
| Margins and ratios | ||||||||||
| Gross margin | 53.4% | 55.0% | 57.6% | 56.9% | 53.9% | 52.4% | 51.4% | 50.9% | 53.9% | 54.6% |
| Operating margin | −4.1% | −5.4% | −3.5% | −63.3% | −12.1% | −9.0% | −15.1% | −63.3% | −13.7% | −12.5% |
| Net margin | 1.9% | 6.2% | 22.7% | −63.1% | −10.8% | −8.4% | −15.5% | −60.7% | −11.6% | −11.5% |
| Free cash flow margin | 19.6% | 14.9% | 12.7% | −8.2% | 6.5% | −3.6% | −1.1% | −10.1% | −5.0% | 0.2% |
| Rule of 40 (growth + FCF margin) | −4.2% | 11.8% | 16.1% | −10.6% | 16.7% | 5.0% | 6.0% | −20.4% | −8.8% | 9.6% |
| Return on capital | — | −2.0% | −1.4% | — | — | — | −10.1% | −59.3% | −24.0% | −24.6% |
| Return on equity | 1.0% | 3.1% | 10.6% | −31.2% | −7.0% | −6.2% | −13.1% | −63.1% | −17.5% | −20.8% |
| Return on assets | 0.7% | 2.3% | 8.0% | −23.3% | −5.5% | −4.8% | −9.7% | −43.4% | −11.4% | −13.4% |
| Net debt to EBITDA | 3.5x | 1.8x | −5.8x | — | — | −4.4x | — | — | — | — |